SCHEMBL6784792

SCHEMBL6784792

O=C1NC(=S)SC1=Cc1ccc(-c2cc(C(F)(F)F)ccc2Cl)o1

nearest known ligand 0.70

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
INSR P06213 3/20 0.67
IGF1R P08069 3/20 0.67
MEN1 O00255 1/20 0.55
POLB P06746 1/20 0.55
KMT2A Q03164 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
RXRA P19793 1/20 0.54
PIK3CG P48736 4/20 0.54
CISD1 Q9NZ45 1/20 0.53
PTP4A3 O75365 1/20 0.53
GSK3A P49840 3/20 0.52
GSK3B P49841 3/20 0.52
PIK3CA P42336 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4538026 0.90 MEN1 (0.67) INSRIGF1RMEN1POLBKMT2A
SCHEMBL4538022 0.90 MEN1 (0.67) INSRIGF1RMEN1POLBKMT2A
SCHEMBL3890812 0.85 IGF1R (0.74) INSRIGF1RMEN1POLBKMT2A
SCHEMBL3890807 0.85 IGF1R (0.74) INSRIGF1RMEN1POLBKMT2A
SCHEMBL13236142 0.85 IGF1R (0.74) INSRIGF1RMEN1POLBKMT2A
SCHEMBL13056359 0.83 SIRT2 (0.61) MEN1POLBKMT2AL3MBTL1GSK3A
SCHEMBL29665101 0.81 MEN1 (0.82) INSRIGF1RMEN1POLBKMT2A
SCHEMBL3362327 0.81 MEN1 (0.82) INSRIGF1RMEN1POLBKMT2A
SCHEMBL3362325 0.81 MEN1 (0.82) INSRIGF1RMEN1POLBKMT2A
SCHEMBL12812715 0.81 MEN1 (0.82) INSRIGF1RMEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040198741-A1 Compounds, compositions and methods for treating or preventing viral infections and associated diseases WYETH 2004-10-07 US disclosed
US-20030195213-A1 Compounds, compositions and methods for treating or preventing viral infections and associated diseases BAILEY THOMAS R (US) 2003-10-16 US disclosed
EP-1128832-A4 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES VIROPHARMA INC (US) 2003-03-05 EP disclosed
US-20020052396-A1 Compounds, compositions and methods for treating or preventing viral infections and associated diseases BAILEY THOMAS R (US) 2002-05-02 US disclosed
EP-1128832-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES Viropharma Incorporated (US) 2001-09-05 EP disclosed
WO-2000010573-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES VIROPHARMA INCORPORATED (US) 2000-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195213-A1 Compounds, compositions and methods for treating or preventing viral infections and associated diseases RXRG, TREH, RARG INSR 1443/4885IGF1R 2948/4885MEN1 3202/4885
US-20020052396-A1 Compounds, compositions and methods for treating or preventing viral infections and associated diseases RXRG, TREH, RARG INSR 1443/4885IGF1R 2948/4885MEN1 3202/4885
US-20040198741-A1 Compounds, compositions and methods for treating or preventing viral infections and associated diseases RXRG, TREH, RARG INSR 1443/4885IGF1R 2948/4885MEN1 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.